You have reached the legacy site. Please visit our new site at

HIV and Coverage of the
61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010)
October 29 - November 2, 2010, Boston, MA
Bristol-Myers Squibb Enhances Co-pay Assistance Program for Entecavir (Baraclude) for Hepatitis B

SUMMARY: Bristol-Myers Squibb this summer expanded its co-pay benefit program for individuals receiving or wishing to use entecavir (Baraclude) who have private insurance policies with out-of-pocket costs. The enhanced program will save eligible patients up to $200 per month for 4 years. Eligible participants may request a Co-Pay Benefit Card from their healthcare providers.

Below is an email advisory from Bristol-Myers Squibb describing the expanded program.

Baraclude (Entecavir) Co-pay Benefit Program Enhancements

Bristol-Myers Squibb enhanced its Baraclude (entecavir) Co-pay Benefit Program beginning on July 1, 2010, for eligible new and existing patients who have out-of-pocket costs through their commercial insurance coverage. We recognize that, especially in this economic environment, out-of-pocket costs for medicine may be prohibitive even for patients who have prescription drug benefits. This program reflects Bristol-Myers Squibb's ongoing commitment to helping patients who need our medicines to access them.

The Baraclude Co-pay Benefit Program will allow eligible patients to save up to $200 of co-pay costs monthly, for the next four years, through December, 2014. Bristol-Myers Squibb will now cover the first $200 of a patient's monthly co-pay or co-insurance costs; the patient will be responsible for any amount over $200. This means that 94.5% of eligible chronic hepatitis B patients with commercial insurance can have a co-pay of $0 per month over the next four years. Restrictions apply to certain patients, including those who reside in Massachusetts and those with prescription benefits funded through Medicare, Medicaid and other federal/state programs.

To access this benefit, eligible patients need to obtain a Co-pay Benefit Card to take to the pharmacy each time they fill their prescription for Baraclude. Benefit cards are available through their healthcare provider. Eligible patients who are currently utilizing our Co-pay Benefit Program for Baraclude do not need to obtain new benefit cards. These patients will begin receiving these new benefits, subject to the new program end date, upon their next use of their Co-pay Benefit Card.

The Co-pay Benefit Card currently is not valid in Massachusetts or for prescriptions purchased under Medicaid, Medicare, or federal or state programs (including state prescription drug programs, or private indemnity or HMO insurance plans, which reimburse patients for the entire cost of the prescription drugs).

This Co-pay Benefit Program is for eligible commercially insured patients only. For patients with chronic hepatitis B who are uninsured or underinsured, Bristol-Myers Squibb offers other programs to support access to medicines. Bristol-Myers Squibb provides our medicines free of charge to those who qualify through our Access Virology Patient Assistance Program and also participates in the pharmaceutical industry's Together Rx Access Program.

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.


Bristol-Myers Squibb. Baraclude (entecavir) Co-pay Benefit Program enhancements. Email advisory. November 12, 2010.




















    Google Custom Search